Wegovy Approved in the US for Cardiovascular Risk Reduction in People with Overweight or Obesity and Established Cardiovascular Disease

Bagsværd, Denmark, 8 March 2024– Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a label expansion for Wegovy based on a supplemental New Drug Application (sNDA) for the indication of reducing...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news